MacroGenics, Inc. (MGNX)
NASDAQ: MGNX · Real-Time Price · USD
3.280
-0.200 (-5.75%)
At close: Nov 20, 2024, 4:00 PM
3.260
-0.020 (-0.61%)
After-hours: Nov 20, 2024, 7:31 PM EST
MacroGenics Revenue
MacroGenics had revenue of $110.71M in the quarter ending September 30, 2024, with 964.81% growth. This brings the company's revenue in the last twelve months to $141.33M, up 16.68% year-over-year. In the year 2023, MacroGenics had annual revenue of $58.75M, down -61.33%.
Revenue (ttm)
$141.33M
Revenue Growth
+16.68%
P/S Ratio
1.45
Revenue / Employee
$416,900
Employees
339
Market Cap
205.86M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 58.75M | -93.19M | -61.33% |
Dec 31, 2022 | 151.94M | 74.49M | 96.19% |
Dec 31, 2021 | 77.45M | -27.44M | -26.16% |
Dec 31, 2020 | 104.88M | 40.70M | 63.40% |
Dec 31, 2019 | 64.19M | 4.07M | 6.76% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
biote | 193.06M |
Personalis | 87.49M |
Genfit | 86.23M |
SOPHiA GENETICS | 64.49M |
Utah Medical Products | 44.08M |
Zentalis Pharmaceuticals | 40.56M |
Molecular Partners AG | 7.11M |
Sera Prognostics | 94.00K |
MGNX News
- 14 days ago - MacroGenics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 15 days ago - MacroGenics, Inc. (MGNX) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 15 days ago - MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results - GlobeNewsWire
- 22 days ago - MacroGenics Announces Leadership Transition - GlobeNewsWire
- 22 days ago - MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call - GlobeNewsWire
- 26 days ago - Rigrodsky Law, P.A. Is Investigating MacroGenics, Inc. On Behalf of Shareholders - Accesswire
- 4 weeks ago - MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA® - Business Wire
- 2 months ago - Shareholders of MacroGenics, Inc. Should Contact The Gross Law Firm Before September 24, 2024 to Discuss Your Rights – MGNX - GlobeNewsWire